---
title: "Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Specific populations questions"
description: "Specific populations questions on Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Shingrix work as well in immunocompromised adults 65 and older (auHSCT study)? Does Shingrix work as well in adults 70 and older? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Specific populations questions

Manufacturer: GlaxoSmithKline Biologicals; GlaxoSmithKline  
Prescribing information: [Shingrix](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF)

Specific populations questions that apply to every indication of Shingrix are on [Shingrix (Zoster Vaccine Recombinant, Adjuvanted), all indications: Specific populations](https://www.evicenter.com/medical-information/shingrix/specific-populations).

## Specific populations

<a id="shingrix-older-immunocompromised"></a>

### Does Shingrix work as well in immunocompromised adults 65 and older (auHSCT study)?

Applies to: Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

> “Of the total number of subjects who received at least 1 dose of SHINGRIX in the auHSCT study (n = 922), 172 
> (18.7%) were aged 65 years and older [see Clinical Studies (14.6)]. There were no clinically meaningful 
> differences in efficacy between these subjects and younger adults (aged 18 through 64 years).”

Source: [SHINGRIX: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=15)

> “Of the total number of subjects who received at least 1 dose of SHINGRIX across the 6 studies in 
> immunocompromised subjects (n = 1,587), 337 (21.2%) were aged 65 years and older. The frequencies of 
> solicited local and general adverse reactions in subjects aged 65 years and older were generally similar to or 
> lower than those reported by younger adults (aged 18 through 64 years).”

Source: [SHINGRIX: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=15)

<a id="shingrix-older-adults"></a>

### Does Shingrix work as well in adults 70 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Of the total number of subjects who received at least 1 dose of SHINGRIX in Studies 1 and 2 (n = 14,645), 
> 2,243 (15%) were aged 60 through 69 years, 6,837 (47%) were aged 70 through 79 years, and 1,921 (13%) were 
> aged 80 years and older. There were no clinically meaningful differences in efficacy across the age groups. [See 
> Clinical Studies (14.1, 14.2, 14.3).]”

Source: [SHINGRIX: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=15)

> “The frequencies of solicited local and general adverse reactions in subjects aged 70 years and older were lower 
> than in younger adults (aged 50 through 69 years). [See Adverse Reactions (6.1).]”

Source: [SHINGRIX: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=15)

## Related pages
- [Medical information: Shingrix (Zoster Vaccine Recombinant, Adjuvanted): Herpes zoster prevention](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention)
- [Indication](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/guidelines)
